Fibrocell Science Inc. regained compliance with Nasdaq's $1 minimum bid price listing requirement.
The Exton, Pa.-based cell and gene therapy company fell out of compliance with the listing rule in January.
Fibrocell Science regains Nasdaq compliance
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Fibrocell Science Inc. regained compliance with Nasdaq's $1 minimum bid price listing requirement.
The Exton, Pa.-based cell and gene therapy company fell out of compliance with the listing rule in January.